Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer research hub

BYLieve: A phase II, multicenter, open-label, three-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients withPIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments.

This study looks at new drug combinations for advanced breast cancer. It's for people whose cancer has a specific change (PIK3CA mutant) and has grown despite previous treatments. Researchers want to see if the new treatments can help people live longer without their cancer getting worse.